top of page
OUR PIPELINE

Publications & Presentations

Uniquity IES2025 Poster.png

Presented at Biennial Congress of the International Eosinophil Society, July 7 - July 11, 2025, Montpellier, France

This poster highlights the role of TSLP in experimental models of type 2 inflammatory diseases.

Download Poster
ATS Poster 2025.png

Presented at American Thoracic Society Annual Conference, May 17 - May 21, 2025, San Francisco, CA

In vitro characterization of solrikitug, a differentiated anti-TSLP antibody, provides distinct epitope binding profile and superior potency compared to tezepelumab.

Download Poster
Uniquity IES2025 Poster.png

Presented at American Academy of Allergy, Asthma & Immunology, Feb 28 - Mar 3, 2025, San Diego, CA

These data demonstrate that a surrogate for solrikitug reduces inflammation in a preclinical model of asthma, with solrikitug showing 10 times more potency than tezepelumab at inhibiting TSLP-induced human dendritic cell activation.

Download Poster
mAB
We are actively expanding our immunology and inflammation pipeline, with a laser focus on therapeutics for indications with limited or no available treatments.
mAB
bottom of page